Core Viewpoint - AtriCure reported a quarterly loss of $0.01 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.11, marking an earnings surprise of +90.91% [1] - The company achieved revenues of $134.27 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.09% and showing a year-over-year increase from $115.91 million [2] Financial Performance - AtriCure has surpassed consensus EPS estimates in all four of the last quarters [2] - The company has also topped consensus revenue estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $139.15 million, and for the current fiscal year, it is -$0.35 on revenues of $530.41 million [7] Stock Performance - AtriCure shares have increased approximately 19.3% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact AtriCure's stock performance [5]

Verano Holdings Corp. (VRNOF) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -140.00%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.05, delivering no surprise.Over the last four quarters, the company has surpas ...

Core Insights - Vita Coco Company, Inc. (COCO) reported quarterly earnings of $0.4 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and showing an increase from $0.32 per share a year ago, resulting in an earnings surprise of +25.00% [1] - The company achieved revenues of $182.31 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 14.82% and increasing from $132.91 million year-over-year [2] - The stock has gained approximately 14.4% since the beginning of the year, while the S&P 500 has increased by 17.2% [3] Earnings Performance - Over the last four quarters, the company has consistently surpassed consensus EPS estimates [2] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $130.38 million, and for the current fiscal year, it is $1.15 on revenues of $585.18 million [7] Market Outlook - The company's stock is currently rated Zacks Rank 5 (Strong Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions prior to the earnings release [6] - The Beverages - Soft drinks industry, to which Vita Coco belongs, is ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - Reynolds Consumer Products reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.39 per share, and showing a slight increase from $0.41 per share a year ago, resulting in an earnings surprise of +7.69% [1] - The company achieved revenues of $931 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.60% and reflecting a year-over-year increase from $910 million [2] - The stock has underperformed the market, losing approximately 12.2% since the beginning of the year, while the S&P 500 has gained 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.55 on revenues of $992.49 million, and for the current fiscal year, it is $1.57 on revenues of $3.65 billion [7] - The estimate revisions trend for Reynolds Consumer Products was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Consumer Products - Discretionary industry is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Ionis Pharmaceuticals reported a quarterly loss of $0.61 per share, which was better than the Zacks Consensus Estimate of a loss of $1.15, representing an earnings surprise of +46.96% [1] - The company posted revenues of $157 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 21.23%, and showing an increase from $134 million in the same quarter last year [2] - Ionis Pharmaceuticals has surpassed consensus EPS estimates and revenue estimates for four consecutive quarters [2] 分组2 - The stock has gained approximately 110.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.18 on revenues of $141.77 million, and for the current fiscal year, it is -$2.10 on revenues of $857.58 million [7] - The Medical - Drugs industry, to which Ionis Pharmaceuticals belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - ProPetro Holding reported a quarterly loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a loss of $0.11, indicating an earnings surprise of +81.82% [1] Financial Performance - ProPetro's revenues for the quarter ended September 2025 were $293.92 million, exceeding the Zacks Consensus Estimate by 14.02%, but down from $360.87 million year-over-year [2] - The company has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times in the same period [2] Stock Performance and Outlook - ProPetro shares have declined approximately 21.8% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at -$0.15 for the upcoming quarter and -$0.22 for the current fiscal year [7] Industry Context - The Oil and Gas - Field Services industry, to which ProPetro belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] - The performance of ProPetro's stock may also be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]

Core Viewpoint - Penske Automotive reported quarterly earnings of $3.23 per share, missing the Zacks Consensus Estimate of $3.48 per share, representing a -7.18% earnings surprise [1]. Financial Performance - The company posted revenues of $7.7 billion for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.58%, compared to $7.59 billion in the same quarter last year [2]. - Over the last four quarters, Penske has surpassed consensus EPS estimates three times and topped revenue estimates two times [2]. Stock Performance - Penske shares have increased by approximately 7% since the beginning of the year, while the S&P 500 has gained 17.2% [3]. - The stock currently holds a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.45 on revenues of $7.63 billion, and for the current fiscal year, it is $14.10 on revenues of $30.67 billion [7]. - The trend of estimate revisions for Penske was unfavorable prior to the earnings release, which may impact future stock performance [6]. Industry Context - The Automotive - Retail and Whole Sales industry is currently ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [8].

Core Viewpoint - Esab reported quarterly earnings of $1.32 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and showing an increase from $1.25 per share a year ago, indicating a positive earnings surprise of +3.94% [1][2] Financial Performance - The company achieved revenues of $687.4 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.06%, and up from $635.6 million in the same quarter last year [2] - Over the last four quarters, Esab has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance and Outlook - Esab shares have increased by approximately 1% since the beginning of the year, while the S&P 500 has gained 17.2%, indicating underperformance relative to the broader market [3] - The future performance of Esab's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $1.36 on revenues of $674.58 million, and for the current fiscal year, it is $5.26 on revenues of $2.66 billion [7] - The estimate revisions trend for Esab was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6] Industry Context - The Metal Products - Procurement and Fabrication industry, to which Esab belongs, is currently ranked in the top 8% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1, suggesting potential for growth within the industry [8]

Core Insights - Chart Industries reported quarterly earnings of $2.78 per share, missing the Zacks Consensus Estimate of $3.01 per share, but showing an increase from $2.18 per share a year ago, resulting in an earnings surprise of -7.64% [1] - The company posted revenues of $1.1 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.95%, compared to $1.06 billion in the same quarter last year [2] - Chart Industries has underperformed the market with a 4.6% increase in shares since the beginning of the year, while the S&P 500 gained 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.04 on revenues of $1.31 billion, and for the current fiscal year, it is $11.29 on revenues of $4.58 billion [7] - The estimate revisions trend for Chart Industries was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Manufacturing - General Industrial industry, to which Chart Industries belongs, is currently in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - Centene (CNC) reported quarterly earnings of $0.5 per share, significantly exceeding the Zacks Consensus Estimate of a loss of $0.21 per share, marking an earnings surprise of +338.10% [1] - The company generated revenues of $49.69 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.35% and showing an increase from $42.02 billion year-over-year [2] Financial Performance - Centene's earnings for the previous year were $1.62 per share, indicating a decline in profitability [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.87, with projected revenues of $47.41 billion, while the estimate for the current fiscal year is $1.69 on $190.45 billion in revenues [7] Market Position - Centene shares have underperformed, losing about 45.2% since the beginning of the year, compared to a 17.2% gain in the S&P 500 [3] - The Zacks Rank for Centene is currently 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Industry Outlook - The Medical - HMOs industry, to which Centene belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Centene's stock performance [5]